The HHS Peptide Enforcement Discretion Policy: What 503A Practices Should Know About the Six Covered Peptides

On 30 October 2026 the Department of Health and Human Services (Fig. 1) published a policy describing when it does not intend to take enforcement action against 503A compounding with six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. [1, 2] The policy applies to state-licensed pharmacies, Federal facilities and licensed physicians, on patient-specific prescriptions, when ten conditions are met, and it lasts until FDA decides by rulemaking whether each peptide belongs on the 503A bulks list. [2]

This guide sets out what the policy covers, the conditions that apply to every compounded product, what the certificate of analysis has to show, and what remains outside it. HHS is taking written comments until 13 November 2026. [1, 8]

The Policy Covers Six Peptides, Each With Its Own Route Limit

Appendix B of the policy fixes each peptide’s identity by amino acid sequence, structure, molecular weight and formula, and limits the routes within the policy. [2] All six were in category 2 of FDA’s interim policy from September 2023 until 22 April 2026 and now sit in FDA’s table of withdrawn nominations. [2, 3] For each, the policy records that FDA’s Center for Drug Evaluation and Research recommended against listing and that the Pharmacy Compounding Advisory Committee voted in favor. [2]

Ten Conditions Apply to Every Compounded Product

HHS states that it does not intend to take action only when all of the following are present. [2] Several restate requirements section 503A already carries, such as the registered establishment, the certificate of analysis and the patient-specific prescription. [4]

• The bulk substance is one of the six in Appendix A.
• It matches the identity in Appendix B and is used only by the routes listed there.
• It comes from a facility registered with FDA under section 510 and is characterized in a valid certificate of analysis that follows FDA’s testing criteria.
• The original manufacturer, as distinct from a later packer, relabeler or distributor, is registered with FDA, complies with CGMP, and has its facility location on the certificate. A registered repacker or reseller in the chain must have validated that manufacturer and its certificate.
• The compounder reports products compounded, serious adverse events and product quality issues to FDA through MedWatch and to the states where products are compounded and sent, and the patient labeling explains how to report. [7]
• The label carries the statement “This is a compounded drug product. Not for resale.”
• Each compounded product contains a single active ingredient from Appendix A.
• For an oral dosage form, the compounder keeps documentation that the formulation achieves adequate oral bioavailability in humans.
• The only delivery device co-packaged with or containing the product is an FDA 510(k)-cleared syringe.
• The product meets every other requirement of the FD&C Act, including sanitary conditions and the patient-specific prescription requirement of section 503A.

The Certificate of Analysis Carries Most of the Weight

HHS gives its reason for the policy plainly: to discourage the widespread use of research-use-only peptides supplied by foreign manufacturers, by offering a more controlled alternative. [2] The control sits in the certificate of analysis. The policy expects it to name the original manufacturer with its FDA Establishment Identifier and address, list any firm that purified or processed the material, and give the batch number, synthesis, release and expiry dates, storage conditions, a CGMP compliance statement, the grade “Intended for human drug compounding”, and a quality-unit signature. [2]

The testing table asks for orthogonal identity methods, meaning at least two procedures based on different physical principles, with 100 percent sequence coverage, together with an HPLC assay against a reference standard (Fig. 2), peptide-related impurities under ICH Q3A, residual solvents, elemental impurities, residual trifluoroacetic acid, counter-ion and water content, bioburden and bacterial endotoxins. [2] Each of these answers a known failure in synthetic peptides: deletion and insertion sequences, racemized residues and oxidized side chains are the impurity classes most often found in peptide medicines. [9] For peptides of eight residues or more, the table adds aggregation and higher-order structure methods, because aggregation is a recognized stability risk for longer chains. [2, 10]

Blends, Intravenous Routes and Other Peptides Fall Outside the Policy

• Multi-peptide products. The single active ingredient condition places any blend of two covered peptides, such as BPC-157 with TB-500 in one vial, outside the policy. HHS links the condition to safety surveillance: adverse events are easier to attribute when a product has one active ingredient. [2]
• Intravenous use. No covered peptide has an intravenous route in Appendix B. [2]
• Other peptides. GHK-Cu, emideltide (DSIP), CJC-1295 and ipamorelin are not in Appendix A. Topical GHK-Cu has its own position, in category 1 of FDA’s list updated 14 May 2026. [2, 3]
• 503B outsourcing facilities. The policy addresses 503A compounding by pharmacies, Federal facilities and physicians. [2, 6]

The Policy Sits Beside the Bulks List Until Rulemaking Decides Each Peptide

The codified 503A bulks list at 21 CFR 216.23 names no peptide, and the policy adds none. [5] Each covered peptide stays under FDA’s withdrawn nominations until a final rule decides whether it goes on the list. [2, 3] HHS may revisit the policy in whole or in part if a safety signal or a product quality issue arises, which is why the reporting condition matters. [2] The human evidence for several of these peptides remains limited; for BPC-157, a 2025 systematic review found the clinical literature small and called for controlled studies. [12]

Oral forms deserve a separate note. Most peptides are poorly absorbed by mouth, and the policy asks the compounder to document human oral bioavailability for the specific formulation before dispensing an oral form. [2, 11]

Comments Are Open Until 13 November 2026

The notice invites written comments for two weeks after publication, through regulations.gov on Docket HHS-OASH-2026-0496. [1, 8] HHS notes that comments may supply evidence FDA can consider in rulemaking, so pharmacies and prescribers with characterization data or reporting experience have a direct channel to the agency. [2]

ExaVeyra Is Reviewing the Policy With Its Pharmacy Partner

ExaVeyra supplies practices through a licensed 503A pharmacy partner on patient-specific prescriptions, with a certificate of analysis available on request for each lot. The team is reviewing the policy peptide by peptide and will publish its position here once it is confirmed. Practices with a question about a specific peptide, a certificate or a documentation requirement are welcome to ask the scientific team directly, and anyone can apply for a free account; NPI verification then unlocks the practitioner portal, exclusive resources and pricing.